Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
COVID-19 Testing
Diagnosis of COVID-19 by assaying bodily fluids or tissues for the presence of COVID-19 antibodies, SARS-COV-2 antigens or the VIRAL RNA of SARS-COV-2.
Year introduced: 2021Date introduced: July 7, 2020
COVID-19 Vaccines
Vaccines or candidate vaccines containing SARS-CoV-2 component antigens, genetic materials, or inactivated SARS-CoV-2 virus, and designed to prevent COVID-19.
COVID-19 Serological Testing
Diagnosis of COVID-19 by assaying bodily fluids or tissues for the presence antibodies specific to SARS-COV-2 or its antigens.
COVID-19 Nucleic Acid Testing
Diagnosis of COVID-19 by assaying bodily fluids or tissues for the presence of the VIRAL RNA of SARS-COV-2.
COVID-19 Serotherapy
Transfer of blood plasma derived from patients who have recovered from COVID-19 to non-immune hosts.
Year introduced: 2023 (2020)Date introduced: July 14, 2022
COVID-19
A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. A coronavirus, SARS-CoV-2 VIRUS, in the genus BETACORONAVIRUS is the causative agent.
Year introduced: 2021(2020)Date introduced: August 9, 2024
SARS-CoV-2
A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis.
Year introduced: 2021(2020)Date introduced: July 7, 2020
Post-Acute COVID-19 Syndrome
Post acute stage of COVID-19 virus infection including signs, symptoms, and conditions that continue or develop after acute COVID-19 infection. Persistent symptoms may include FATIGUE; DYSPNEA; and MEMORY LOSS.
Year introduced: 2023(2020)Date introduced: August 9, 2024
COVID-19 Drug Treatment
The use of DRUGS to treat COVID19 or its symptoms.
2019-nCoV Vaccine mRNA-1273
mRNA vaccine against SARS-CoV-2, developed by Moderna.
Year introduced: 2022(2021)Date introduced: July 9, 2021
SARS-CoV-2 variants [Supplementary Concept]
Sequence variants of SARS-COV-2 virus when compared to the reference sequence (NC_045512.2). Many are under investigation for various mutations and their potential impact on COVID-19 (e.g, transmissibility, diagnosis, vaccine effectiveness or clinical presentation or severity). For instance variant B.1.1.7 is characterized by a set of mutations including N501Y on the spike protein which binds human ACE2 PROTEIN. There are more than 900 registered variants as of February 2021.
Date introduced: December 21, 2020
spike protein, SARS-CoV-2 [Supplementary Concept]
Date introduced: March 19, 2020
pediatric multisystem inflammatory disease, COVID-19 related [Supplementary Concept]
Paediatric multisystem inflammatory syndrome temporally associated with COVID-19
Date introduced: May 10, 2020
Baiya SARS-CoV-2 VAX COVID-19 vaccine [Supplementary Concept]
plant (Nicotiana benthamiana) produced SARS-CoV-2 receptor binding domain protein subunit vaccine
Date introduced: May 25, 2022
ChAdOx1 nCoV-19
A viral vector vaccine against SARS-CoV-2 developed by AstraZeneca. Its vector encodes the SARS-CoV-2 Spike protein.
nucleocapsid phosphoprotein, SARS-CoV-2 [Supplementary Concept]
RefSeq NC_045512
Date introduced: October 1, 2020
adult multisystem inflammatory disease, COVID-19 related [Supplementary Concept]
Date introduced: July 8, 2021
3C-like proteinase, SARS-CoV-2 [Supplementary Concept]
Date introduced: February 5, 2025
Pandemic Preparedness
Various plans outlined for the care of casualties and the maintenance of services in a PANDEMIC. Pandemic preparedness plan includes CAPACITY BUILDING in flexible infrastructure and SENTINEL SURVEILLANCE.
Year introduced: 2024Date introduced: July 26, 2023
BIBP COVID-19 vaccine [Supplementary Concept]
SARS-CoV-2 whole virus inactivated, produced in vero cells. Can also be referred to as more general Sinopharm COVID-19 vaccine. Do not confuse with Sinovac COVID-19 vaccine or sinopharm WIBP COVID-19 vaccine
Date introduced: July 6, 2022